文献速递口腔修复与种植口腔黏膜病

自身免疫性疾病患者的口腔种植治疗:范围综述

Dental Implant Therapy in Patients With Autoimmune Diseases: A Scoping Review.
PubMed 文献 · Clin Oral Implants Res · 2025-04-03

本范围综述检索MEDLINE、Cochrane Library和Embase(截至2024年4月29日),纳入87项关于自身免疫性疾病患者种植治疗的研究,以病例报告和回顾性研究为主。种植体生存率总体为85.3%–100%,多数种植体丢失发生在修复负载前;总体科学证据水平较低。

要点

  • 自身免疫性疾病患者种植体生存率总体为85.3%–100%,多数丢失发生在早期。
  • 糖皮质激素是最常使用的免疫抑制剂。
  • 口腔扁平苔藓未控制发作患者中,一项研究55枚种植体丢失42枚。

核心结论

  • 在中短期随访中,自身免疫性疾病患者(其中许多人接受免疫抑制剂)的种植治疗总体可预测,种植体生存率高。
  • 种植体丢失主要发生在修复负载前。
  • 黏膜表现型自身免疫性疾病患者在黏膜病变得到良好治疗的前提下,似乎可从种植支持修复中获益。
  • 总体可获得的科学证据水平较低。

研究设计与样本

  • 范围综述,电子检索MEDLINE(PubMed)、Cochrane Library和Embase,检索日期为2024年4月29日。
  • 纳入英文临床研究,共检索到6319条记录,最终纳入87项研究。
  • 纳入研究以病例报告和回顾性研究为主,可用证据中大量研究处于证据等级较低位置。

主要发现

  • 种植体生存率总体为85.3%–100%,其中46.7%–100%的种植体丢失发生在早期。
  • 糖皮质激素是最常使用的免疫抑制剂。
  • 口腔扁平苔藓患者种植体生存率虽高,但一项研究中未治疗发作期口腔扁平苔藓患者55枚种植体中丢失42枚。
  • 多个结局指标的报告存在异质性。

临床怎么用

  • 作者认为,自身免疫性疾病患者种植治疗总体可预测,种植体生存率高。
  • 作者认为,黏膜表现型自身免疫性疾病患者在黏膜病变得到良好治疗的前提下,似乎可从种植支持修复中获益。

局限性

  • 可用证据以病例报告和回顾性研究为主,大量研究处于证据等级较低位置。
  • 多个结局指标的报告存在异质性。
  • 总体可获得的科学证据水平较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this scoping review is to determine the effects of autoimmune diseases (ADs) and the agents used for treatment on dental implant survival and biologic outcomes. MATERIAL AND METHODS: An electronic database search was performed in MEDLINE (PubMed), The Cochrane Library, and Embase on 29-04-2024. Clinical studies in English on implant therapy in patients with ADs were potentially eligible. Recorded variables included study information, patient demographics, ADs, immunosuppressants, antiresorptives, dental implant survival rate, biologic complications, and oral health-related quality of life. Descriptive statistics were performed. RESULTS: A total of 6319 records were retrieved through database search and hand search, of which 87 studies could be included with an overweight of case reports and retrospective studies. The available evidence was characterized by a high number of studies placed low on the hierarchy of evidence. Several outcome parameters were heterogeneously reported. Glucocorticoids were the most frequently administrated immunosuppressant. The implant survival rate was overall 85.3%-100%; hereof, 46.7%-100% of implant losses occurred early, indicating a certain risk of implant failure. Despite high implant survival in oral lichen planus (OLP) patients, one study lost 42 of 55 implants in patients with untreated flare-up of OLP. CONCLUSIONS: Dental implant treatment is generally predictable with a high implant survival rate, after mid-term follow-up, in patients with ADs, of whom many receive immunosuppressants. Implant losses occurred predominantly before prosthetic loading. Particularly, patients with mucosal manifestations of their ADs seem to benefit from implant-supported restorations provided mucosal lesions are well treated. However, overall low-level scientific evidence was available.

来源:Clin Oral Implants Res,查看原文。版权归原作者所有。

引用

  1. Hyldahl E, Schliephake H, Jensen SS, et al. Dental Implant Therapy in Patients With Autoimmune Diseases: A Scoping Review. Clin Oral Implants Res. 2025. PMID: 40181226. doi:10.1111/clr.14440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。